{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:39:17Z","timestamp":1792471157014,"version":"4.5.0"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T00:00:00Z","timestamp":1757980800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Benvitimod (tapinarof), an aryl hydrocarbon receptor (AhR) agonist approved for treating plaque psoriasis, is being investigated as a potential treatment for atopic dermatitis (AD). The aim of this study was to evaluate the efficacy and safety of benvitimod 1% cream in patients aged 2 years or older with AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This randomized controlled trial enrolled 271 Chinese patients with AD aged \u22652 years, who received either benvitimod 1% cream (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 183) or vehicle cream (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 88) twice daily for 8 weeks in a 2:1 ratio at 35 sites in China from June to November 2023. The primary endpoint was the proportion of patients achieving a 75% improvement in the Eczema Area and Severity Index (EASI) 75 at week 8. Secondary endpoints included achievement of Investigator\u2019s Global Assessment (IGA) scores of 0\/1, 90% EASI improvement (EASI 90), and \u22653-point reduction in Peak Pruritus Numerical Rating Scale (PP-NRS). Treatment-emergent adverse events (TEAEs) were monitored for safety evaluation. Furthermore, a subset of patients (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 43) opted into a 44-week open-label extension.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At week 8, a significantly higher proportion of patients treated with benvitimod achieved EASI 75 compared to those receiving vehicle (54.4% [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 183] vs. 25.5% [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 88];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). The benvitimod group also showed superior results across all secondary endpoints: IGA 0\/1 (46.2% [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 183]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 21.4% [\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 88];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), EASI 90 (33.9% [58\/171]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 13.5% [10\/74];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001), and \u22653-point decrease in PP-NRS (54.0% [47\/87]\n                      <jats:italic toggle=\"yes\">vs<\/jats:italic>\n                      . 27.9% [12\/43];\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.01). TEAEs occurred in 51.4% (94\/183) of benvitimod-treated patients\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      43.2% (38\/88) of vehicle-treated patients, with most events being mild to moderate in severity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Benvitimod 1% cream demonstrated favorable efficacy and safety in adult and pediatric patients with AD, supporting its potential as a novel topical treatment option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration:<\/jats:title>\n                    <jats:p>chinadrugtrials.org.cn, CTR20231413.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003769","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T12:01:17Z","timestamp":1758110477000},"page":"3076-3083","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of benvitimod 1% cream for atopic dermatitis in patients aged 2 years and older: A phase III randomized clinical trial"],"prefix":"10.1097","volume":"139","author":[{"given":"Yan","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hunan Children\u2019s Hospital, Changsha, Hunan 410007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chengdu Second People\u2019s Hospital, Chengdu, Sichuan 610017, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Beijing Children\u2019s Hospital, Capital Medical University, Beijing 100045, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhong","family":"Jiao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sanmenxia Central Hospital, Sanmenxia, Henan 472000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Dermatology, China\u2013Japan Friendship Hospital, Beijing 100029, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shanghai Tenth People\u2019s Hospital, Shanghai 200072, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunpeng","family":"Bian","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nanyang Central Hospital, Nanyang, Henan 473009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Ci","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui 241001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjian","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Changde Hospital, Xiangya School of Medicine, Central South University (The First People\u2019s Hospital of Changde City), Changde, Hunan 415003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiechi","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuhan University People\u2019s Hospital, Wuhan, Hubei 430060, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang Provincial People\u2019s Hospital, Hangzhou, Zhejiang 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuping","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuxi No. 2 People\u2019s Hospital, Wuxi, Jiangsu 214002, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin 300120, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Qilu Hospital of Shandong University, Jinan, Shandong 250012, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genhui","family":"Chen","sequence":"additional","affiliation":[{"name":"Thederma Shanghai, Shanghai 201203, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"On behalf of study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,16]]},"reference":[{"key":"R1-20261020","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2006.01047.x","article-title":"Quality of life and childhood atopic dermatitis: The misery of living with childhood eczema","volume":"60","author":"Lewis-Jones","year":"2006","journal-title":"Int J Clin Pract"},{"key":"R2-20261020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061298","article-title":"Quality of life and psychological impact in patients with atopic dermatitis","volume":"10","author":"Talamonti","year":"2021","journal-title":"J Clin Med"},{"key":"R3-20261020","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"R4-20261020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: An expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"R5-20261020","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4168\/aair.2018.10.3.207","article-title":"Significance of skin barrier dysfunction in atopic dermatitis","volume":"10","author":"Kim","year":"2018","journal-title":"Allergy Asthma Immunol Res"},{"key":"R6-20261020","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jaip.2014.03.006","article-title":"Skin barrier and immune dysregulation in atopic dermatitis: An evolving story with important clinical implications","volume":"2","author":"Czarnowicki","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R7-20261020","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","article-title":"Pathophysiology of atopic dermatitis: Clinical implications","volume":"40","author":"Kim","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"R8-20261020","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/all.15486","article-title":"Single-cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis","volume":"78","author":"Zhang","year":"2023","journal-title":"Allergy"},{"key":"R9-20261020","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/exd.13336","article-title":"Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment","volume":"27","author":"Guttman-Yassky","year":"2018","journal-title":"Exp Dermatol"},{"key":"R10-20261020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11882-015-0567-4","article-title":"The role of the skin microbiome in atopic dermatitis","volume":"15","author":"Williams","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"R11-20261020","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.anai.2023.12.022","article-title":"Topical steroid withdrawal and atopic dermatitis","volume":"132","author":"Marshall","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R12-20261020","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs","volume":"79","author":"M\u00fcller","year":"2024","journal-title":"Allergy"},{"key":"R13-20261020","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.jaad.2021.04.103","article-title":"Tapinarof cream 1% once daily and benvitimod 1% twice daily are 2 distinct topical medications","volume":"85","author":"Gold","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"R14-20261020","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1097\/CM9.0000000000001221","article-title":"A double-blind, randomized, placebo-and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis","volume":"133","author":"Cai","year":"2020","journal-title":"Chin Med J"},{"key":"R15-20261020","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans","volume":"137","author":"Smith","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R16-20261020","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.jid.2023.07.027","article-title":"Benvitimod inhibits IL-4\u2013and IL-13\u2013induced tight junction impairment by activating AHR\/ARNT pathway and inhibiting STAT6 phosphorylation in human keratinocytes","volume":"144","author":"Wang","year":"2024","journal-title":"J Invest Dermatol"},{"key":"R17-20261020","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9113741","article-title":"Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4\u2013JAK\u2013STAT6\/STAT3 axis: Pathogenic and therapeutic implications in atopic dermatitis","volume":"9","author":"Furue","year":"2020","journal-title":"J Clin Med"},{"key":"R18-20261020","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2103629","article-title":"Phase 3 trials of tapinarof cream for plaque psoriasis","volume":"385","author":"Lebwohl","year":"2021","journal-title":"New Engl J Med"},{"key":"R19-20261020","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/CM9.0000000000002489","article-title":"A multi-center, double-blind, randomized, placebo-and positive-controlled phase II clinical study of benvitimod for the treatment of atopic dermatitis","volume":"136","author":"Cai","year":"2023","journal-title":"Chin Med J"},{"key":"R20-20261020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","article-title":"Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials","volume":"91","author":"Silverberg","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"R21-20261020","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/1346-8138.17451","article-title":"Tapinarof cream for the treatment of atopic dermatitis: Efficacy and safety results from two Japanese phase 3 trials","volume":"51","author":"Igarashi","year":"2024","journal-title":"J Dermatol"},{"key":"R22-20261020","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaad.2022.06.1171","article-title":"One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial","volume":"87","author":"Strober","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"R23-20261020","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/s41467-025-56574-7","article-title":"Structural basis for the ligand-dependent activation of heterodimeric AHR-ARNT complex","volume":"16","author":"Diao","year":"2025","journal-title":"Nat Commun"},{"key":"R24-20261020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00403-024-03268-7","article-title":"Benvitimod upregulates filaggrin, involucrin and loricrin expressions via aryl hydrocarbon receptor-OVO-like 1 axis","volume":"316","author":"Jia","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"R25-20261020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2014.04.019","article-title":"Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions","volume":"40","author":"Di Meglio","year":"2014","journal-title":"Immunity"},{"key":"R26-20261020","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41586-023-06508-4","article-title":"Endothelial sensing of AHR ligands regulates intestinal homeostasis","volume":"621","author":"Wiggins","year":"2023","journal-title":"Nature"},{"key":"R27-20261020","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/eji.201747121","article-title":"AhR activation increases IL-2 production by alloreactive CD4+ T cells initiating the differentiation of mucosal-homing Tim3+ Lag3+ Tr1 cells","volume":"47","author":"Ehrlich","year":"2017","journal-title":"Eur J Immunol"},{"key":"R28-20261020","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1084\/jem.20160789","article-title":"The aryl hydrocarbon receptor controls cell-fate decisions in B cells","volume":"214","author":"Vaidyanathan","year":"2017","journal-title":"J Exp Med"},{"key":"R29-20261020","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.celrep.2019.10.018","article-title":"Aryl hydrocarbon receptor contributes to the transcriptional program of IL-10-producing regulatory B cells","volume":"29","author":"Piper","year":"2019","journal-title":"Cell Rep"},{"key":"R30-20261020","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41586-020-1975-8","article-title":"Neuronal programming by microbiota regulates intestinal physiology","volume":"578","author":"Obata","year":"2020","journal-title":"Nature"},{"key":"R31-20261020","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cell.2011.09.025","article-title":"Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation","volume":"147","author":"Li","year":"2011","journal-title":"Cell"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003769","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:01:58Z","timestamp":1792468918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003769"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,16]]},"references-count":31,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003769","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,16]]},"assertion":[{"value":"2025-03-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}